Summary

Other Scenarios:

Buyer: Medicis Pharmaceutical Corporation (MRX) Last Price: 28.76 Market Cap.: 1.61B
Target: Alpharma Inc. (ALO) Last Price: 25.44 Market Cap.: 1.10B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
*Healthcare 926
Biopharmaceuticals 372
Medical Devices   261
Nutritional Health   28
Outsourced Services   65
Veterinary Products and Services   6

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 16)
  • Plexion/Plexion TS/Plexion SCT (Sodium Sulfacetamide/Sulfur)
  • Dynacin (Minocycline Hydrochloride)
  • Solodyn Extended Release Tablet (Minocycline HCl)
  • Ziana Gel (Clindamycin/Tretinoin)
Target (Total: 12)
  • Triple Antibiotic Cream (Bacitracin Zinc/Neomycin/Polymyxin B Sulfate)
  • Bacitracin Zinc
  • Tolnaftate
  • M-Zole 7 Dual Pack (Miconazole)
Buyer
  • Perlane (Hyaluronic Acid)
  • Restylane (Hyaluronic Acid)
Target
  • Alpharma Inc.
  • Alpharma Active Pharmaceutical Ingredients Manufacturing
  • Alpharma Animal Health Division

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 4)
  • sanofi-aventis (ADR) (SNY)
  • Patheon, Inc. (PTI:CA)
  • Q-Med, Inc. (QMED)
  • Contract Pharmaceuticals Limited
Target (Total: 7)
  • Bayer AG (ADR) (BAY)
  • Koninklijke DSM N.V. (ADR) (RDSMY)
  • Cambrex Corporation (CBM)
  • Applix, Inc. (APLX)
Buyer (Total: 4)
  • McKesson Corporation (MCK)
  • Cardinal Health, Inc. (CAH)
  • BioMarin Pharmaceutical Inc. (BMRN)
  • Taro Pharmaceutical Industries Ltd. (TAROF)
Target (Total: 3)
  • Alcon, Inc. (ACL)
  • MGi Pharma, Inc. (MOGN)
  • Enzon Pharmaceuticals, Inc. (ENZN)

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 391 1,400
Revenue Per Employee 978,208.3 481,550.8
Total Revenue 95.1 168.1
Total Expenses 86.2 151.1
Other Revenue 0.0 0.0
Cost of Revenue 10.5 71.6
SG&A Expense 62.3 63.2
Research & Development 8.0 18.4
Other Operating Expense 0.0 0.0
Operating Income 8.9 17.0
Unusual Income 0.0 -2.1
LT Debt to Capital 45.94 28.91
Fwd P/E 25.34 19.11
Fwd P/Rev 3.63 1.54
Book Value 533.1 737.8
Curr Portion of LTD/Cap Lease 0.0 0.0

Individual Company Summary

Focused

Buyer

Focused (): *Healthcare > Biopharmaceuticals > Dermatology

Target

Focused (): *Healthcare > Biopharmaceuticals

Business Description

Buyer

Medicis Pharmaceutical Corporation (Medicis) is an independent specialty pharmaceutical company focused primarily on helping patients attain a healthy and youthful appearance and self-image through the development and marketing in the United States of products for the treatment of dermatological, aesthetic and podiatric conditions. It also markets products in Canada for the treatment of dermatological and aesthetic conditions. It offers a range of products addressing various conditions or aesthetic improvements, including facial wrinkles, acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, skin and skin-structure infections, seborrheic dermatitis and cosmesis (improvement in the texture and appearance of skin). It offers 17 branded products, including OMNICEF (cefdinir), RESTYLANE (hyaluronic acid), SOLODYN (minocycline HCl, USP), TRIAZ (benzoyl peroxide), VANOS (fluocinonide) Cream 0.1%, and ZIANA (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel.

Target

Alpharma Inc. is a global specialty pharmaceutical company that develops, manufactures and markets pharmaceutical products for humans and animals. It has three business segments. The Pharmaceuticals segment (formerly known as Branded Pharmaceuticals) markets one branded pharmaceutical prescription product that is contract manufactured by a third party, which is a pain medication sold under the trademark KADIAN. The Active Pharmaceutical Ingredients segment develops, manufactures and markets a line of fermentation-based active pharmaceutical ingredients and one chemically synthesized active pharmaceutical ingredient that are used, primarily by third parties, in the manufacture of finished dose pharmaceutical products. The Animal Health segment develops, registers, manufactures and markets medicated feed additives, and water soluble vitamins type substances for food producing animals, which include poultry, cattle and swine. On March 31, 2006, Alpharma sold ParMed Pharmaceuticals Inc.

Deal Summary

Key Ratios

  Buyer Target
Gross Margin % 89.15 57.64
Operating Margin % -9.91 12.91
Quick Ratio 6.77 3.48
Current Ratio 7.53 4.5
Coverage Ratio -0.61 0.16
Total Assets 1,084.0 1,232.6
Return on Equity % 4.12 8.78
Return on Assets % 2.03 5.26
Cash+ ST Inv. Per Share 8.99 9.33
Total Debt 453.1 300.0
Total Debt to Equity % 84.98 40.66
Total Debt to Tangible Equity % 148.43 64.94
Debt to Asset % 41.79 24.34

Product Summary

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
  
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
  
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
  
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
  
Medical Devices  
Plastic/Reconstructive Surgery
The Plastic/Reconstructive Surgery Subsector includes medical devices that treat and modify a patient's external appearance.
  
Nutritional Health  
Dietary/Naturopathic Supplements
The Dietary/Naturopathic Subsector includes nutritional biochemicals and nutrients derived from natural sources that are intended to support health.
  
Outsourced Services  
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
  
Veterinary Products and Services  
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.

Target Products:

  • Alpharma Animal Health Division
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Dermatology  
Acne  
Rosacea  
Para Aminobenzoic Acid (PABA) Inhibitors
Therapeutics that treat chronic inflammatory disorder of the face characterized by redness and pimple formation by inhibiting bacterial folic acid synthesis.

Buyer Products:

  • Plexion/Plexion TS/Plexion SCT (Sodium Sulfacetamide/Sulfur)
  
Vulgaris  
Antibacterial Agents  
Tetracyclines
Therapeutics that treat acne caused by bacterial infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.

Buyer Products:

  • Dynacin (Minocycline Hydrochloride)
  • Solodyn Extended Release Tablet (Minocycline HCl)
  
Antibacterial Agents/Retinoids
Therapeutics that treat acne by preventing bacterial growth and helping in cell differentiation.

Buyer Products:

  • Ziana Gel (Clindamycin/Tretinoin)
  
Keratolytic Agents
Therapeutics that soften, separate, and cause the shedding of skin.

Buyer Products:

  • Triaz (Benzoyl Peroxide)
  
Para Aminobenzoic Acid (PABA) Inhibitors
Therapeutics that treat bacterial infections of the skin by inhibiting a bacterial enzyme responsible for synthesis of folic acid.

Buyer Products:

  • Plexion/Plexion TS/Plexion SCT (Sodium Sulfacetamide/Sulfur)
  
Aging Disorders  
Wrinkles  
Acetylcholine Inhibitors
Therapeutics that treat wrinkling through prevention of muscle contractions that can result in the formation of facial lines.

Buyer Products:

  • Reloxin (Botulinum Toxin Type A)
  
Lesion/Scaling Disorders  
Dermatitis  
Atopic (Eczema)  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat atopic dermatoses by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.

Buyer Products:

  • Synalar (Fluocinolone Acetonide)
  
Seborrheic (Dandruff)  
Antifungal Agents  
Imidazoles
Therapeutics that treat and prevent skin diseases caused by fungi.

Buyer Products:

  • Loprox (Ciclopirox)
  
Para Aminobenzoic Acid (PABA) Inhibitors
Therapeutics that treat bacterial infections of the skin by inhibiting a bacterial enzyme responsible for synthesis of folic acid.

Buyer Products:

  • Plexion/Plexion TS/Plexion SCT (Sodium Sulfacetamide/Sulfur)
  
Dermatoses  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.

Buyer Products:

  • Vanos (Fluocinonide)
  • Lidex (Fluocinonide)
  
Pruritus  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.

Buyer Products:

  • Vanos (Fluocinonide)
  
Psoriasis  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.

Buyer Products:

  • Synalar (Fluocinolone Acetonide)
  
Pigmentation Disorders  
Hyperpigmentation  
Enzymatic Oxidation Inhibitors
Therapeutics that treat disorders characterized by darkening of the skin by inhibiting metabolic processes of pigment producing skin cells.

Buyer Products:

  • Esoterica (Hydroquinone)
  
Endocrinology/Metabolism  
Intermediary Metabolism Disorders  
Urea Cycle Disorders  
Glutamine Acetylyzing Agents
Therapeutics that conjugate with glutamine to help excrete nitrogen waste.

Buyer Products:

  • Ammonul (Sodium Phenylacetate, Sodium Benzoate)
  • Buphenyl (Sodium Phenylbutyrate)
  
Immunology  
Autoimmune Disorders  
Psoriasis  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat a chronic autoimmune disease characterized by softening, separating, causing the shedding of the horny layer of the skin with a steroidal compound.

Buyer Products:

  • Synalar (Fluocinolone Acetonide)
  • Vanos (Fluocinonide)
  
Infectious Diseases
Bacterial
Antibacterial Agents
Broad Spectrum  
Antibiotics  
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.

Buyer Products:

  • Omnicef (Cefdinir)
  
Tetracyclines
Therapeutics that treat a wide variety of infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.

Buyer Products:

  • Dynacin (Minocycline Hydrochloride)
  
Narrow Spectrum  
Dermatology  
Skin/Soft Tissue Infections  
Aminoglycosides/Polypeptides
Therapeutics that treat dermal infections by inhibiting bacterial cell wall synthesis.

Target Products:

  • Triple Antibiotic Cream (Bacitracin Zinc/Neomycin/Polymyxin B Sulfate)
  
Ophthalmology  
Ocular Infections  
Polypeptides
Therapeutics that treat bacterial infections of the eye by damaging the cell membrane.

Target Products:

  • Bacitracin Zinc
  
Mycological (Fungal)
Antifungal Agents
Narrow Spectrum
Dermatology
Tinea Corporis (Ringworm)
Azoles  
Imidazoles
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Loprox (Ciclopirox)
  
Thiocarbamates
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by stunting the growth of the branching filaments.

Target Products:

  • Tolnaftate
  
Tinea Cruris (Jock Itch)
Azoles  
Imidazoles
Therapeutics that treat fungal infections of the groin and perineum by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Loprox (Ciclopirox)
  
Thiocarbamates
Therapeutics that treat fungal infections of the groin and perineum by stunting the growth of the branching filaments.

Target Products:

  • Tolnaftate
  
Tinea Pedis
Azoles  
Imidazoles
Therapeutics that treat fungal infections of the feet by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Loprox (Ciclopirox)
  
Thiocarbamates
Therapeutics that treat fungal infections of the feet by stunting the growth of the branching filaments.

Target Products:

  • Tolnaftate
  
Tinea Versicolor  
Azoles  
Imidazoles
Therapeutics that treat fungal infections of skin exposed to the sun characterized by patches of depigmentation by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Loprox (Ciclopirox)
  
Urology  
Vaginal Candidiasis  
Azoles  
Imidazoles
Therapeutics that treat fungal infections of the female reproductive organ caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Target Products:

  • M-Zole 7 Dual Pack (Miconazole)
  • M-Zole 3 Combination Pack (Miconazole)
  
Pain Management  
Anesthesia  
General (Systemic)  
Adjunctive  
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters both the perception of pain as well as the emotional response to pain.

Target Products:

  • Kadian (Morphine Sulphate Extended Release)
  
Narcotics  
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain.

Target Products:

  • Kadian (Morphine Sulphate Extended Release)
  • Kadian NT (Abuse Resistant Morphine Sulphate/Naltrexone))
  
Non-Narcotics  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain by non-specifically inhibiting the action of cyclooxygenase.

Target Products:

  • Ibuprofen Oral Suspension
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of pain in early stages of clinical research where human subject is involved.

Target Products:

  • Abuse Deterrent Oxycodone
  
Medical Devices  
Plastic/Reconstructive Surgery  
Treatment  
Wrinkle Removal  
Hyaluronic Acid  
Nutritional Health  
Dietary/Naturopathic Supplements  
General Health
Products consisting of dietary/naturopathic supplements that are intended to support general health.

Target Products:

  • Alpharma Inc.
  
Outsourced Services  
Development/Manufacturing Services  
Contract Manufacturing Organizations (CMO)  
Pharmaceuticals  
Final Dosage Forms
Contract Manufacturing Organizations (CMO) that produce large quantities of drug products in final dosage forms ready to be sold to end users.

Target Products:

  • Alpharma Active Pharmaceutical Ingredients Manufacturing
  
Veterinary Products and Services  
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.

Target Products:

  • Alpharma Animal Health Division
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Johnson & Johnson n/a 173,127.270 16.36 15.01 3.03 2.92 n/a
Bristol Myers Squibb Co. n/a 56,365.380 36.11 20.87 3.18 3.00 15.42
Biovail Corporation (USA) n/a 3,092.357 13.05 11.03 2.83 3.76 5.53
Taro Pharmaceutical Industries Ltd. n/a 269.772 47.52 n/a 0.91 0.85 1.14
Buyer
  Johnson & Johnson n/a 173,127.270 16.36 15.01 3.03 2.92 n/a
sanofi-aventis (ADR) n/a 111,120.171 20.31 11.51 2.76 2.90 n/a
Target
  Johnson & Johnson n/a 173,127.270 16.36 15.01 3.03 2.92 n/a
Novartis AG (ADR) n/a 124,169.978 20.39 16.22 3.27 3.33 5.49
Abbott Laboratories n/a 77,064.208 40.02 18.18 3.20 3.20 n/a
Eli Lilly & Co. n/a 62,395.048 28.65 16.48 3.68 3.58 n/a
Bristol Myers Squibb Co. n/a 56,365.380 36.11 20.87 3.18 3.00 15.42
Teva Pharmaceutical Industries Ltd (ADR) n/a 33,646.920 17.74 19.04 3.82 3.73 24.81
Endo Pharmaceuticals n/a 4,441.277 25.46 19.61 4.63 4.30 5.27
King Pharmaceuticals, Inc. n/a 4,078.925 11.52 9.66 2.02 2.03 3.48
Bausch & Lomb Inc. n/a 3,512.859 163.40 29.46 1.51 1.44 12.74
Biovail Corporation (USA) n/a 3,092.357 13.05 11.03 2.83 3.76 5.53
Perrigo Company n/a 1,714.123 25.47 21.40 1.20 1.22 4.76
XenoPort, Inc. n/a 1,074.236 n/a -71.98 41.55 17.19 13.02
Acura Pharmaceuticals, Inc. n/a 756.244 n/a n/a n/a n/a n/a
Penwest Pharmaceuticals n/a 297.393 n/a -8.83 88.08 85.25 8.25
Taro Pharmaceutical Industries Ltd. n/a 269.772 47.52 n/a 0.91 0.85 1.14
DepoMed, Inc. n/a 105.858 n/a -2.67 8.79 3.90 n/a
BioDelivery Sciences International, Inc. n/a 71.160 n/a -1.96 25.68 n/a n/a
Elite Pharmaceuticals, Inc. n/a 49.114 n/a n/a 42.90 3.72 14.16
DOV Pharmaceutical, Inc. n/a 6.953 n/a n/a 0.21 n/a 0.45

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  sanofi-aventis (ADR) n/a 111,120.171 20.31 11.51 2.76 2.90 n/a
Patheon, Inc. n/a 353.243 n/a n/a 0.49 n/a 1.67
Q-Med, Inc. n/a 63.071 n/a -5.26 3.07 1.61 6.50
Contract Pharmaceuticals Limited n/a n/a n/a n/a n/a n/a n/a
Target
  Bayer AG (ADR) n/a 52,005.822 10.04 14.83 1.28 1.22 n/a
Koninklijke DSM N.V. (ADR) n/a 9,163.700 13.57 n/a 0.78 n/a 1.40
Cambrex Corporation n/a 381.298 2.16 31.91 0.82 n/a 0.87
Applix, Inc. n/a 213.412 21.36 37.43 3.74 3.51 10.02
PDI, Inc. n/a 152.364 35.55 -6.98 0.78 n/a 1.29
Kaken Pharmaceutical Co., Ltd. n/a n/a n/a n/a n/a n/a n/a
Actavis Group hf. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  McKesson Corporation 56.80% 16,611.381 18.19 17.84 0.18 0.17 6.25
Cardinal Health, Inc. 19.30% 25,156.014 18.64 19.24 0.29 0.29 7.27
BioMarin Pharmaceutical Inc. n/a 1,768.502 n/a -84.64 18.97 14.92 13.31
Taro Pharmaceutical Industries Ltd. n/a 269.772 47.52 n/a 0.91 0.85 1.14
Target
  Alcon, Inc. n/a 41,512.710 29.68 26.47 8.20 7.61 20.37
MGi Pharma, Inc. n/a 2,022.287 n/a 66.97 5.72 5.14 n/a
Enzon Pharmaceuticals, Inc. n/a 323.855 n/a -41.50 1.78 1.85 n/a

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  sanofi-aventis (ADR) n/a 111,120.171 20.31 11.51 2.76 2.90 n/a
Abbott Laboratories n/a 77,064.208 40.02 18.18 3.20 3.20 n/a
Cardinal Health, Inc. n/a 25,156.014 18.64 19.24 0.29 0.29 7.27
McKesson Corporation n/a 16,611.381 18.19 17.84 0.18 0.17 6.25
BioMarin Pharmaceutical Inc. n/a 1,768.502 n/a -84.64 18.97 14.92 13.31
Patheon, Inc. n/a 353.243 n/a n/a 0.49 n/a 1.67
Taro Pharmaceutical Industries Ltd. n/a 269.772 47.52 n/a 0.91 0.85 1.14
Q-Med, Inc. n/a 63.071 n/a -5.26 3.07 1.61 6.50
Ipsen S.A. n/a n/a n/a n/a n/a n/a n/a
AAIPharma Inc. n/a n/a n/a n/a n/a n/a n/a
Contract Pharmaceuticals Limited n/a n/a n/a n/a n/a n/a n/a
Dow Pharmaceutical Sciences, Inc. n/a n/a n/a n/a n/a n/a n/a
Astellas Pharma Inc. n/a n/a n/a n/a n/a n/a n/a
Target
  Bayer AG (ADR) n/a 52,005.822 10.04 14.83 1.28 1.22 n/a
Alcon, Inc. n/a 41,512.710 29.68 26.47 8.20 7.61 20.37
Teva Pharmaceutical Industries Ltd (ADR) n/a 33,646.920 17.74 19.04 3.82 3.73 24.81
Koninklijke DSM N.V. (ADR) n/a 9,163.700 13.57 n/a 0.78 n/a 1.40
MGi Pharma, Inc. n/a 2,022.287 n/a 66.97 5.72 5.14 n/a
Cambrex Corporation n/a 381.298 2.16 31.91 0.82 n/a 0.87
Enzon Pharmaceuticals, Inc. n/a 323.855 n/a -41.50 1.78 1.85 n/a
Actavis Group hf. n/a n/a n/a n/a n/a n/a n/a
Kaken Pharmaceutical Co., Ltd. n/a n/a n/a n/a n/a n/a n/a
Tris Pharma, Inc. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 369.2 662.9 1,032.1
Other Revenue 0.0 0.0 0.0
Total Revenue 369.2 662.9 1,032.1
Cost of Revenue 40.1 280.8 320.9
SG&A Expense 217.9 252.1 469.9
Depreciation & Amortization 22.6 0.0 22.6
Research & Development 72.6 54.8 127.5
Interest Expense 0.0 0.0 0.0
Other Operating Expense 0.0 0.0 0.0
Unusual Expense (Income) 52.6 -10.3 42.3
Total Expenses 405.8 577.4 983.1
Operating Income -36.6 85.6 49.0
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng 22.1 13.7 35.8
Other, Net 0.0 -0.8 -0.8
Income Before Taxes -14.4 99.9 85.4
Income Taxes -36.4 35.1 -1.3
Income After Taxes 22.0 64.8 86.8
Net Income - Excl. Xord. Items 22.0 64.8 86.8
Discontinued Operations 0.0 -3.7 -3.7
Net Income - Incl. Xord. Items 22.0 61.1 83.1
Income Avail. to Common 22.0 61.1 83.1
Share Items
Basic Avg. Shares Outstanding 55.6 42.3 97.9
Basic EPS - Excl. Xord. Items 0.40 1.53 0.89
Basic EPS - Incl. Xord. Items 0.40 1.44 0.85
Full Dilution Adjustment 1.7 0.0 1.7
Fully Diluted Shares Outstanding 71.7 42.8 114.6
F.D. EPS - Excl. Xord. Items 0.31 1.51 0.76
F.D. EPS - Incl. Xord. Items 0.31 1.43 0.73
Dividends Per Common Share 0.12 0.09 0.21
Balance Sheet
Assets
Cash and Equivalents 83.9 399.9 483.8
ST Investments 560.6 0.0 560.6
Accounts Receivable 18.0 106.9 124.9
Inventory 30.8 118.4 149.3
Prepayments and Advances 0.0 29.1 29.1
Other Current Assets 43.7 0.0 43.7
Current Assets 737.0 654.4 1,391.5
Accum D&A 0.0 0.0 0.0
PPE, Net 7.5 237.2 244.7
Goodwill & Intangibles 227.9 275.9 503.8
Other Assets 0.0 0.0 0.0
Other LT Assets 111.7 65.0 176.7
Total Assets 1,084.0 1,232.6 2,316.7
Liabilities
Accounts Payable 51.4 44.9 96.3
Payable/Accrued 0.0 0.0 0.0
Accrued Expenses 0.0 100.6 100.6
ST Debt 0.0 0.0 0.0
Other (Current) Liabilities 46.5 0.0 46.5
Current Liab. 97.9 145.5 243.4
LT Debt 453.1 300.0 753.1
Total LT Debt 453.1 300.0 753.1
Deferred Taxes 0.0 23.0 23.0
Other LT Liab. 0.0 26.3 26.3
Total Liabilities 550.9 494.8 1,045.7
Shareholders Equity
Common Stock 1.0 11.1 12.1
Additional Paid in Capital 615.2 1,121.4 1,736.5
Retained Earnings 259.2 -140.7 118.5
Treasure Stock -342.9 -315.0 -657.9
Other Equity 0.7 61.1 61.8
Total Equity 533.1 737.8 1,271.0
Total Liab. & Equity 1,084.0 1,232.6 2,316.7
Shares Outstanding 55.8 43.4 99.2
Cash Flow
Operating Cash Flow
CF Net Income 22.0 61.1 83.1
CF Depreciation 22.6 46.4 69.0
CF Deferred Taxes -57.1 28.9 -28.1
Other Non-Cash Items 91.2 1.5 92.7
Change in Working Capital 17.5 -59.9 -42.4
Total Cash From Operating Activities 96.3 78.0 174.3
Investing Cash Flow (not calculated)
Capital Expenditures -8.0 -39.6 -47.6
Other Investing Cash Flows -274.3 0.0 -274.3
Total Cash From Investing Activities -282.2 -39.6 -321.8
Financing Cash Flow (not calculated)
Dividends Paid -6.6 -7.4 -14.0
Purchase Or Sale of Stock 27.7 -300.0 -272.2
Purchase and Retirement of Debt 0.0 295.6 295.6
Other Financing Cash Flow 3.0 3.8 6.8
Total Cash From Financing Activities 24.1 -8.1 16.1
Exchange Rate Effects -0.1 3.2 3.1
Net Change in Cash -161.9 33.5 -128.4
Cash Taxes Paid 35.7 -37.6 -1.9
Cash Interest Paid 0.0 -4.8 -4.8